Elacestrant

Drug Profile

Elacestrant

Alternative Names: RAD-1901

Latest Information Update: 10 Jun 2017

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Developer Radius Health Inc.
  • Class Osteoporosis therapies; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Selective estrogen receptor degraders; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Vasomotor symptoms
  • Phase I Breast cancer

Most Recent Events

  • 05 Jun 2017 Interim safety and efficacy data from a phase I trial in Breast cancer released by Radius Health
  • 01 May 2017 Radius Health completes enrolment in its phase Ib trial for Breast Cancer in Belgium and the Netherlands (NCT02650817)
  • 01 May 2017 Radius Health completes enrolment in its phase Ib trial for Breast Cancer in USA (NCT02338349)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top